PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SNY vs. MRK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SNY and MRK is 0.40, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.4

Performance

SNY vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sanofi (SNY) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

250.00%300.00%350.00%400.00%450.00%NovemberDecember2025FebruaryMarchApril
285.10%
341.15%
SNY
MRK

Key characteristics

Sharpe Ratio

SNY:

0.50

MRK:

-1.35

Sortino Ratio

SNY:

0.94

MRK:

-1.79

Omega Ratio

SNY:

1.11

MRK:

0.76

Calmar Ratio

SNY:

0.54

MRK:

-0.87

Martin Ratio

SNY:

1.34

MRK:

-1.67

Ulcer Index

SNY:

8.73%

MRK:

19.10%

Daily Std Dev

SNY:

23.28%

MRK:

23.69%

Max Drawdown

SNY:

-46.65%

MRK:

-68.62%

Current Drawdown

SNY:

-9.21%

MRK:

-33.34%

Fundamentals

Market Cap

SNY:

$134.06B

MRK:

$218.76B

EPS

SNY:

$2.37

MRK:

$6.74

PE Ratio

SNY:

22.76

MRK:

12.85

PEG Ratio

SNY:

0.97

MRK:

0.80

Total Revenue (TTM)

SNY:

$33.17B

MRK:

$48.39B

Gross Profit (TTM)

SNY:

$23.42B

MRK:

$39.64B

EBITDA (TTM)

SNY:

$7.32B

MRK:

$19.98B

Returns By Period

In the year-to-date period, SNY achieves a 11.86% return, which is significantly higher than MRK's -12.20% return. Over the past 10 years, SNY has underperformed MRK with an annualized return of 4.11%, while MRK has yielded a comparatively higher 8.01% annualized return.


SNY

YTD

11.86%

1M

-4.55%

6M

-4.09%

1Y

13.10%

5Y*

6.97%

10Y*

4.11%

MRK

YTD

-12.20%

1M

-6.23%

6M

-21.44%

1Y

-31.59%

5Y*

6.80%

10Y*

8.01%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SNY vs. MRK — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNY
The Risk-Adjusted Performance Rank of SNY is 6868
Overall Rank
The Sharpe Ratio Rank of SNY is 7171
Sharpe Ratio Rank
The Sortino Ratio Rank of SNY is 6464
Sortino Ratio Rank
The Omega Ratio Rank of SNY is 6161
Omega Ratio Rank
The Calmar Ratio Rank of SNY is 7575
Calmar Ratio Rank
The Martin Ratio Rank of SNY is 6868
Martin Ratio Rank

MRK
The Risk-Adjusted Performance Rank of MRK is 44
Overall Rank
The Sharpe Ratio Rank of MRK is 11
Sharpe Ratio Rank
The Sortino Ratio Rank of MRK is 44
Sortino Ratio Rank
The Omega Ratio Rank of MRK is 44
Omega Ratio Rank
The Calmar Ratio Rank of MRK is 44
Calmar Ratio Rank
The Martin Ratio Rank of MRK is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SNY vs. MRK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SNY, currently valued at 0.50, compared to the broader market-2.00-1.000.001.002.003.00
SNY: 0.50
MRK: -1.35
The chart of Sortino ratio for SNY, currently valued at 0.94, compared to the broader market-6.00-4.00-2.000.002.004.00
SNY: 0.94
MRK: -1.79
The chart of Omega ratio for SNY, currently valued at 1.11, compared to the broader market0.501.001.502.00
SNY: 1.11
MRK: 0.76
The chart of Calmar ratio for SNY, currently valued at 0.54, compared to the broader market0.001.002.003.004.005.00
SNY: 0.54
MRK: -0.87
The chart of Martin ratio for SNY, currently valued at 1.34, compared to the broader market-5.000.005.0010.0015.0020.00
SNY: 1.34
MRK: -1.67

The current SNY Sharpe Ratio is 0.50, which is higher than the MRK Sharpe Ratio of -1.35. The chart below compares the historical Sharpe Ratios of SNY and MRK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.50-1.00-0.500.000.501.00NovemberDecember2025FebruaryMarchApril
0.50
-1.35
SNY
MRK

Dividends

SNY vs. MRK - Dividend Comparison

SNY's dividend yield for the trailing twelve months is around 3.78%, more than MRK's 3.65% yield.


TTM20242023202220212020201920182017201620152014
SNY
Sanofi
3.78%4.22%3.83%4.22%3.80%3.61%3.46%4.29%3.67%4.03%3.79%4.19%
MRK
Merck & Co., Inc.
3.65%3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.42%3.11%

Drawdowns

SNY vs. MRK - Drawdown Comparison

The maximum SNY drawdown since its inception was -46.65%, smaller than the maximum MRK drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for SNY and MRK. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-9.21%
-33.34%
SNY
MRK

Volatility

SNY vs. MRK - Volatility Comparison

The current volatility for Sanofi (SNY) is 5.88%, while Merck & Co., Inc. (MRK) has a volatility of 7.16%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%NovemberDecember2025FebruaryMarchApril
5.88%
7.16%
SNY
MRK

Financials

SNY vs. MRK - Financials Comparison

This section allows you to compare key financial metrics between Sanofi and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab